Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 27, 2023

SELL
$57.89 - $64.73 $2,315 - $2,589
-40 Reduced 7.78%
474 $27,000
Q1 2023

May 12, 2023

SELL
$65.71 - $74.53 $788 - $894
-12 Reduced 2.28%
514 $35,000
Q3 2022

Nov 10, 2022

SELL
$0.13 - $76.84 $2 - $1,536
-20 Reduced 3.66%
526 $37,000
Q2 2022

Aug 11, 2022

SELL
$72.62 - $79.98 $23,601 - $25,993
-325 Reduced 37.31%
546 $42,000
Q1 2022

May 12, 2022

SELL
$61.48 - $73.72 $424,765 - $509,331
-6,909 Reduced 88.8%
871 $64,000
Q4 2021

Feb 11, 2022

BUY
$53.63 - $62.52 $234,470 - $273,337
4,372 Added 128.29%
7,780 $485,000
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $5,917 - $6,931
-100 Reduced 2.85%
3,408 $202,000
Q2 2021

Aug 09, 2021

SELL
$61.91 - $67.42 $1,857 - $2,022
-30 Reduced 0.85%
3,508 $234,000
Q4 2020

Feb 11, 2021

BUY
$57.74 - $65.43 $2,771 - $3,140
48 Added 1.38%
3,538 $219,000
Q3 2020

Nov 12, 2020

SELL
$57.43 - $63.64 $17,516 - $19,410
-305 Reduced 8.04%
3,490 $210,000
Q1 2020

May 01, 2020

SELL
$46.4 - $67.43 $8,816 - $12,811
-190 Reduced 4.77%
3,795 $212,000
Q4 2019

Jan 29, 2020

SELL
$49.21 - $64.19 $28,787 - $37,551
-585 Reduced 12.8%
3,985 $256,000
Q3 2019

Oct 24, 2019

BUY
$42.77 - $50.71 $15,824 - $18,762
370 Added 8.81%
4,570 $232,000
Q1 2019

Apr 25, 2019

SELL
$45.12 - $53.8 $27,072 - $32,280
-600 Reduced 12.5%
4,200 $200,000
Q4 2018

Jan 23, 2019

SELL
$48.76 - $63.23 $2,194 - $2,845
-45 Reduced 0.93%
4,800 $250,000
Q3 2018

Nov 06, 2018

BUY
$55.19 - $62.25 $262,428 - $295,998
4,755 Added 5283.33%
4,845 $301,000
Q2 2018

Aug 07, 2018

BUY
$50.53 - $62.98 $4,547 - $5,668
90 New
90 $5,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Cedar Wealth Management, LLC Portfolio

Follow Cedar Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cedar Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cedar Wealth Management, LLC with notifications on news.